» Articles » PMID: 24137761

Vitamin D Deficiency in Patients with Erythropoietic Protoporphyria

Overview
Publisher Wiley
Date 2013 Oct 19
PMID 24137761
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The main symptom of patients with erythropoietic protoporphyria (EPP) is painful photosensitivity, starting within minutes of sun exposure and leading to sun-avoidance. As 80-100% of vitamin D is synthesized under the influence of sunlight, we investigated whether the avoidance of sunlight exposure in the Dutch EPP patient population causes vitamin D deficiency. Furthermore, we studied the relation between vitamin D levels, total erythrocyte protoporphyrin and quality of life.

Methods: In a cross-sectional study of 48 Dutch EPP patients (mean age 41.4 years; range 16-77; 23 male, 25 female), we assessed serum 25-hydroxyvitamin D (25(OH)D) levels between June and November 2007, as well as total erythrocyte protoporphyrin (TEP) levels and Dermatology Life Quality Index (DLQI) scores.

Results: Mean serum 25(OH)D was 66 nmol/L (range 18-140, quartiles 36, 87). Twenty-two patients (46%; 15 male, 7 female) were vitamin D deficient. There was a significant difference (p = 0.029) in mean serum 25(OH)D between female (mean 75 nmol/L, range 18-140) and male patients (mean 55 nmol/L, range 18-115). The level of serum 25(OH)D showed a negative correlation with total erythrocyte protoporphyrin (TEP) (Pearson rank correlation (r(p)) = -0.337; p = 0.034). Serum 25(OH)D was inversely associated with scores of the Dermatology Life Quality Index (DLQI) (Spearman's rho correlation (r(s)) = -0.486; p = 0.001).

Conclusions: The prevalence of vitamin D deficiency is high in the Dutch EPP population, especially in male patients, and correlates with the severity of EPP. Screening for and treatment of vitamin D deficiency should therefore be implemented in the care of these patients.

Citing Articles

Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyria: The EPP Impact Questionnaire (EPIQ).

Mathias S, Burke L, Colwell H, Mensing G, Savage W, Naik H Patient Relat Outcome Meas. 2024; 15:17-30.

PMID: 38375415 PMC: 10875163. DOI: 10.2147/PROM.S438892.


Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity.

Qi Q, Gu R, Zhu J, Anderson K, Ma X Drug Metab Dispos. 2024; 52(11):1201-1207.

PMID: 38351044 PMC: 11495668. DOI: 10.1124/dmd.123.001582.


Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.

Hussain Z, Qi Q, Zhu J, Anderson K, Ma X Pharmacol Ther. 2023; 248:108487.

PMID: 37392940 PMC: 10529234. DOI: 10.1016/j.pharmthera.2023.108487.


How I treat erythropoietic protoporphyria and X-linked protoporphyria.

Leaf R, Dickey A Blood. 2023; 141(24):2921-2931.

PMID: 36898083 PMC: 10646811. DOI: 10.1182/blood.2022018688.


Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.

Dickey A, Naik H, Keel S, Levy C, Beaven S, Elmariah S J Am Acad Dermatol. 2022; 89(6):1227-1237.

PMID: 36041558 PMC: 9968824. DOI: 10.1016/j.jaad.2022.08.036.